In sum, our study demonstrates that the CD34+ and CD3+ cellular composition of the donor graft significantly influences post-HCT outcomes in adults with AML undergoing myeloablative HCT with HLA-matched related or unrelated peripheral blood stem cells. Here, CD34 is linked to acute myeloid leukemia.